Bio-Rad boosts liquid biopsy chops with RainDance buy

Blood
Billerica, Massachusetts-based RainDance specializes in droplet-based genomic tools.

Bio-Rad has kicked off 2017 with a bang, announcing it has inked a deal to acquire genetic analysis player RainDance Technologies for an undisclosed amount. The news comes a week after Bio-Rad and Illumina debuted their NGS solution for single-cell analysis.

Billerica, Massachusetts-based RainDance specializes in droplet-based genomic tools, which labs and research institutions use to investigate genetic variations in a range of diseases as well as to research liquid biopsy.

It markets the low-cost NGS target-enriching system, ThunderBolts, as well as the RainDrop Plus Digital PCR system. Digital PCR is gaining ground as an alternative to traditional PCR as it returns more accurate results. Droplet-based tech divides the PCR reaction into many smaller reactions. Greater accuracy is especially important in liquid biopsy, where researchers are trying to catch cancer earlier by pinpointing circulating tumor cells in the blood.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"[RainDance’s] droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital PCR,” Bio-Rad CEO Norman Schwartz said in a statement. “We look forward to expanding our offering to provide life science and clinical diagnostics customers with solutions for a wide range of nucleic acid detection applications."

The deal is slated to close in the first quarter.

RainDance announced in March 2015 that it would file for a $60 million IPO, but withdrew five months later due to “market conditions.”

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.